Global Cancer Monoclonal Antibodies Market 2017 Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2022 - Reuters

 

Global Cancer Monoclonal Antibodies Market 2017 Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2022

Global Cancer Monoclonal Antibodies Market 2017 Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2022

Mon Jun 19, 2017 - 11:00am UTC

OrbisResearch.com has published new research report on “Cancer Monoclonal Antibodies Market by Application by type by Conjugated Cancer therapies and by region-Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016-2021)” to its database.

Global Cancer Monoclonal Antibodies Market 2017 Primary Research, Risk Analysis, Product Research, Trends and Forecast by 2022

Dallas, United States – June 19, 2017

The Global Cancer Monoclonal Antibodies Market was currently estimated to be at a USD 27 billion in 2015 and is poised to reach USD 45 billion by the end of 2020 with a CAGR of 11.2% from 2015 to 2020. Cancer is a severe diseases causing millions of death worldwide every year. Cancer starts from a single cell and genetically transforms a normal cell in to tumour cell and is gradually spread to other cells. With the dramatic increase in the number of people affected by cancer, many pharmaceutical players started to invest on monoclonal antibodies. While the drugs are used for the treatment of cancer, drugs like chemotherapy agents have adverse side effects as they affect the normal cells as well along with cancerous cells. This prompted the increased usage of Monoclonal Antibodies for the treatment of cancer.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/326656

Monoclonal Antibodies having the potential to offer less toxic and efficient therapeutic alternatives to the patients have been emerging in the recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer. Monoclonal Antibodies (mAbs) are mono-specific antibodies bodies comprising of identical immune cells that are clones of a single parent cells and are directed to a specific cellular targets. Thus Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.

The dramatic increase of the number of cancer patients has led many pharmaceutical players to invest in monoclonal antibodies market. Increasing investment in research and development of genomic studies, technological advancements in genetic sequencing and target gene selection, specificity of monoclonal antibodies to target only the cancer cells with no side effects are the some of the driving forces of the market. Increased prevalence of cancer being the key driver for the monoclonal antibodies market, it is expected to grow lucratively in the next 5 years with the presence of strong products in the pipeline. However, there are few restraints for the growth of the market like high development cost being the major one. And also, stringent regulatory guidelines, long durations required for the research and development of antibodies, longer periods of clinical trials are some of the hurdles faced by the market.

Buy the report@http://www.orbisresearch.com/contact/purchase/326656

The global Monoclonal Antibodies are segmented bases on the application as Liver, Breast, Blood, Brain, Hodgkins and Non-Hodgkins lymphoma, Colorectal, leukaemia and others. The market is also analysed based on segmention by type of monoclonal antibodies as murine antibodies, chimeric and humanised antibodies and fully humanized antibodies. The market is also segemented by Conjugated Cancer therapies using Monoclonal Antibodies as Immunoliposome, Radioimmunotherapy, ADEPT, immunocytokines and others. The global market is also categorised based on the geographical region as North America, Europe, Asia-Pacific, Middle East & Africa and Latin America.

The highly customizable nature of the monoclonal antibodies are attracting various organizations, research institutes and multinational companies to use it as a tool to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, glaxosmithkline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics and Spectrum Pharmaceuticals.

Major Points From The Table Of Contents:
Introduction
Research Methodology
Overview
Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
Market Segmentation
Geographical Analysis
Strategic Analysis
Market Leaders’ Analysis
Competitive Landscape
Market Outlook and Investment Opportunities

List Of Tables:
Global Cancer Monoclonal Antibodies Market By Region, From
Global Cancer Monoclonal Antibodies Market By Application, From
Global Liver Market By Region, From
Global Breast Market By Region, From
Global Brain Market By Region, From
Global Blood Market By Region, From
Global Hodgkins and Non-Hodgkins lymphoma Market By Region, From
Global Colorectal Market By Region, From
Global Leukaemia Market By Region, From
Global Others Market By Region, From
Global Cancer Monoclonal Antibodies Market By Type, From
Global Murine Antibodies Market By Region, From
Global Chimeric and Humanised Antibodies Market By Region, From
Global Fully Humanized Antibodies Market By Region, From
Global Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From
Global Immunoliposome Market By Region, From
Global Radioimmunotherapy Market By Region, From

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Name: Hector Costello
Email: sales@orbisresearch.com
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817

This content is produced independently of Reuters Editorial News. For content inquiry, please contact reuters@vcnewsnetwork.com

For content enquiry, please reach us at

Latest News >

Vertex Ventures to co-lead US$11 million round in Israeli transcription startup Verbit

Verbit uses AI to combine software with human transcribers to improve quality, speed and price of services.

06:29am UTC

Indonesia’s Electronic Signature Startup PrivyID secures US$5 million in Series A

PrivyID is Indonesia’s DocuSign and it enables users and enterprises to digitally sign and transfer document online with an integrated audit trailer.

05:03am UTC

Online Content Marketplace GetCRAFT in talks to raise US$5 million Series A by 2018

GetCRAFT is an online content marketplace, which connects brands and agencies in Southeast Asia with content creators and marketers across the globe.

05:05am UTC

Malaysian wealth fund Khazanah to buy Prince Court Medical Centre from Petronas

OrbisResearch.com has published new research report on “Cancer Monoclonal Antibodies Market by Application by type by Conjugated Cancer therapies and by region-Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016-2021)” to its database. Dallas, United States – June 19, 2017 — The Global Cancer Monoclonal Antibodies Market was currently estimated to be at a […]

06:57am UTC

VinaCapital to invest US$10 million in Vietnamese real estate firm Ricons

VinaCapital said the investment is in line with the company’s strategy to invest in company benefiting from strong domestic growth.

05:03am UTC